MOUNTAIN VIEW, Calif., Jan. 25, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced results of a clinical study evaluating the use of IRIDEX' MicroPulse laser therapy. The study examined the tissue-sparing therapy's effectiveness with patients diagnosed with central serous chorioretinopathy (CSC).(1) The study concluded tissue-sparing subvisible MicroPulse laser is superior to anti-VEGF injections for CSC, also known as CSR, an eye disease, which results in blurred vision typically perceived as a dark spot in the center of the field of vision. It primarily affects men between the ages of 20-50 and is often associated with type-A personalities.
"Because of the absence of laser-induced retinal damage discernable at any time postoperatively, subvisible MicroPulse photocoagulation, with no focal burn end point (or its consequences), represents an elegant medical approach and a true clinical alternative," stated co-author Prof. Frank Koch, head of the vitreo-retinal department at the University Eye Clinic of Johann Wolfgang Goethe University in Frankfurt, Germany.
"MicroPulse laser therapy is producing the kind of clinical results that we believe will fuel a paradigm shift in the treatment of retinal diseases," Dr. Dominik Beck President & CEO stated. "MicroPulse is a tissue-sparing therapy that we believe brings long-term therapeutic benefits with no collateral damage and can increase visual function in a very cost-effective manner. Causing no collateral damage at any time postoperatively allows for MicroPulse applications to be delivered over the entire area of CSC leakage including those near to and directly over the center of the macula (the fovea). This is a powerful vote for safety. While CSC does not impact a large population, this study is additional clinical evidence of the efficacy and safety in using MicroPulse laser therapy to treat a broader class of retinal diseases that impacts millions of Americans."
This was the first comparative, prospective evaluation of subvisible MicroPulse laser treatment and anti-VEGF injections in the treatment of CSC with regard to changes in subretinal fluid and visual function. The results indicated superior subretinal fluid resolution for MicroPulse laser compared to anti-VEGF injections, and superior improvement in visual acuity and other visual functions.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts